1036028-06-4

Basic information

• Product Name: (1H-pyrrolo[2,3-b]pyridin-5-yl)carbamic acid benzyl ester
• Synonyms: (1H-pyrrolo[2,3-b]pyridin-5-yl)carbamic acid benzyl ester
• CAS NO: 1036028-06-4
• Molecular Weight: 267.287
• Mol File: 1036028-06-4.mol

Chemical Properties

• CAS DataBase Reference: (1H-pyrrolo[2,3-b]pyridin-5-yl)carbamic acid benzyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (1H-pyrrolo[2,3-b]pyridin-5-yl)carbamic acid benzyl ester(1036028-06-4)
• EPA Substance Registry System: (1H-pyrrolo[2,3-b]pyridin-5-yl)carbamic acid benzyl ester(1036028-06-4)

Safety Data

• Hazardous Substances Data: 1036028-06-4(Hazardous Substances Data)

Upstream product

• 754214-41-0 1-(tert-butyl-dimethyl-silanyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid 
• 100-51-6 benzyl alcohol 
• 100960-07-4 1H-pyrrolo[2,3-b]pyridin-5-amine 
• 501-53-1 benzyl chloroformate 

Downstream Products

• 1036028-07-5 benzyl 3-bromo-1H-pyrrolo[2,3-b]pyridin-5-ylcarbamate 
• 1086423-68-8 2,6-dichloro-3,5-dimethoxy-N-(1H-pyrrolo[2,3-b]pyridin-5-yl)benzamide 
• 100960-07-4 1H-pyrrolo[2,3-b]pyridin-5-amine 

Relevant articles and documents

INHIBITORS OF BRUTON'S TYROSINE KINASE

This application discloses compounds according to generic Formula I: wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.

PROTEIN KINASE INHIBITORS AND METHODS FOR USING THEREOF

The invention provides compounds of formula (l) and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, and methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of AIk, AbI, Aurora-A, B-Raf, C-Raf, Bcr-Abl, BRK, BIk, Bmx, BTK, c-Kit, c-RAF, CSK, c-SRC, EphBl, EphB2, EphB4, FLTl, Fms, Flt3, Fyn, FRK3, JAK2, KDR, Lck, Lyn, PDGFRalpha, PDGFRbeta, PKCalpha, SAPK2alpha, Src, SIK, Syk, Tie2 and TrkB kinases.

5-CYAN0-4- (PYRROLO [2, 3B] PYRIDINE-3-YL) -PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS

The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.